The landscape of colorectal cancer (CRC) screening is undergoing a seismic shift. For decades, the gold standard for detecting early-stage cancer and precancerous polyps has been the invasive colonoscopy, often supplemented in recent years by non-invasive stool-based tests. However, the next frontier in oncology diagnostics is increasingly clear: the liquid biopsy.
New study results from Freenome, a biotechnology firm specializing in multiomics, have injected fresh momentum into the blood-based screening market. With an updated “SimpleScreen” assay demonstrating improved sensitivity, the company is positioning itself to challenge incumbents. Critically, its strategic partnership with healthcare giant Abbott has analysts at Evercore ISI predicting a potential shift in market dominance, as the two firms work in tandem to normalize blood-based screening for the average-risk population.
The Evolution of Screening: From Stool to Serum
Colorectal cancer remains one of the most preventable yet lethal forms of malignancy globally. Early detection is the single most significant factor in patient survival. While the American Cancer Society and other health organizations recommend screening for all adults starting at age 45, adherence rates have historically lagged due to the "yuck factor" associated with stool samples and the procedural anxiety and time commitment required for colonoscopies.
Blood-based tests, often referred to as liquid biopsies, are designed to bridge this gap. By detecting circulating tumor DNA (ctDNA) and other protein markers, these tests aim to identify signs of malignancy through a routine blood draw—a process familiar to millions of patients.
Freenome’s latest clinical data highlights a significant step forward in this technology. Its updated SimpleScreen test reported an 80.4% sensitivity for detecting colorectal cancer, an improvement over its first-generation iteration, which recorded 79.2%. Perhaps more importantly, the company reported a marked improvement in detecting advanced precancerous lesions—from 12.5% to 18.2%. While these figures remain lower than the diagnostic accuracy of a colonoscopy, their potential for high patient adherence makes them a potent public health tool.
Chronology: A Path to Regulatory and Commercial Milestones
The trajectory of Freenome’s SimpleScreen test has been defined by a series of rigorous clinical trials and strategic commercial alignment:
- Initial Development: Freenome began development of its multiomics platform, focusing on a combination of cell-free DNA (cfDNA) and protein markers to enhance diagnostic specificity.
- The Abbott Alliance: Recognizing the logistical and distribution power required to penetrate the primary care market, Freenome entered a strategic commercial collaboration with Abbott. This partnership is not merely transactional; it involves a multi-year R&D program aimed at refining assay performance.
- August 2024: Freenome formally submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its first-generation SimpleScreen CRC test.
- Mid-2026 Expectations: The company anticipates that the FDA review process for the initial application will conclude by mid-2026.
- The Supplemental Strategy: Following the data release on the "next-generation" test, Freenome announced plans to submit a supplemental PMA to the FDA, effectively upgrading the regulatory pathway to account for the improved sensitivity metrics.
Supporting Data: Why Sensitivity Matters
The clinical performance of any screening tool is measured by its ability to identify the presence of disease (sensitivity) while avoiding false positives (specificity). In the crowded CRC market, Freenome is now operating in the shadow—and the direct competition—of Guardant Health’s Shield test.
Guardant’s Shield currently holds the distinction of being the first blood test approved by the FDA for primary colorectal cancer screening in average-risk adults aged 45 and older. Freenome’s improved 80.4% sensitivity score is a direct challenge to this market leadership.
According to Dr. Aasma Shaukat, a professor of medicine at the New York University Grossman School of Medicine, the performance gains reported by Freenome are significant. "Improvements in sensitivity move the updated SimpleScreen test closer to matching the performance of certain stool-based CRC screening tests, with potentially higher patient adherence," Shaukat noted. For the healthcare system, the value proposition is clear: if a patient is more likely to show up for a blood draw than to collect a stool sample, the "real-world" effectiveness of the test often outperforms a more accurate test with lower patient compliance.
Official Responses and Financial Implications
The collaboration between Freenome and Abbott is structured to incentivize performance. Central to this is a $70 million milestone payment contingent on two factors: the successful FDA approval of the next-generation SimpleScreen test and the seamless technical transfer of the assay to Abbott’s diagnostic infrastructure.
"This is about more than just the test," noted industry analysts. "It is about the reach." Abbott’s existing footprint in the diagnostics space, bolstered by its previous acquisitions and its established position in the stool-based testing market (notably via its relationship with Exact Sciences’ Cologuard), gives it a unique vantage point. By offering both a stool-based test and, eventually, a high-performance blood-based test, Abbott is positioning itself as a "one-stop shop" for GI health screening.
Freenome management has maintained that their focus remains on the "patient journey." By providing a less invasive entry point, the company hopes to capture the segment of the population that has been historically "unscreened."
Implications for the Future of Diagnostic Medicine
The entry of high-sensitivity blood tests into the primary care setting will likely force a reorganization of how gastroenterologists and primary care physicians (PCPs) approach CRC prevention.
1. The "Screening Ladder"
Clinicians may soon adopt a tiered approach to screening. A blood-based test could serve as the "front door," with patients who test positive being fast-tracked for a follow-up colonoscopy. This would allow for a more efficient allocation of colonoscopy resources, reserving the procedure for those at the highest risk.
2. Market Competition and Pricing
As Abbott and Guardant Health vie for market share, the economics of screening will likely shift. Insurance providers, including Medicare and private payers, will be closely watching the cost-effectiveness of these blood tests compared to traditional methods. The $70 million milestone payment between Freenome and Abbott underscores the massive financial stakes involved in securing a foothold in the routine screening market.
3. The R&D Pipeline
The collaboration between Freenome and Abbott is not static. The multi-year R&D program mentioned by the companies suggests that we are likely to see further iterations of the SimpleScreen test. In the world of liquid biopsy, data is the currency; as the company collects more real-world evidence, the accuracy of their algorithms is expected to improve, further narrowing the gap between blood-based screening and colonoscopy.
Conclusion
The recent data from Freenome, combined with the formidable distribution power of Abbott, represents a critical pivot point in the fight against colorectal cancer. While the clinical community continues to debate the relative merits of stool-based versus blood-based screening, the primary goal remains universal: to increase the number of patients who undergo regular, life-saving screening.
As the FDA continues its review of the SimpleScreen assay, all eyes will be on the 2026 timeline. Should the next-generation test receive regulatory clearance, the landscape of primary care will be fundamentally altered. For patients, the promise is simple: a less invasive, more convenient way to detect a disease that, when caught early, is among the most treatable cancers in modern medicine. For industry giants like Abbott, the stakes are equally high—securing the future of a multibillion-dollar market that is finally moving from the laboratory to the waiting room.
